As an approximate biological negative control, we included a parallel analysis of 36,292 type 2 diabetes patients using SGLT2 inhibitors (bexagliflozin, canagliflozian, empagliflozin, dapagliflozin, and ertugliflozin), which are also first-line oral agents for diabetes, but act by a different, insulin-independent mechanism, without significant effects on tissue adiposity. Here, SLC5A2 is linked to type 2 diabetes mellitus.